Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension-Reference-Cited by-同舟云学术

Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension

Published:2008-10-15 Issue:8 Volume:178 Page:861-869
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Baliga Reshma S.,Zhao Lan,Madhani Melanie,Lopez-Torondel Belen,Visintin Cristina,Selwood David,Wilkins Martin R.,MacAllister Raymond J.,Hobbs Adrian J.

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference45 articles.

1. Pulmonary Arterial Hypertension

2. Endothelial Dysfunction in Pulmonary Hypertension

3. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.

4. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

5. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphodiesterase 9A inhibition improves aging-related increase in pulmonary vascular resistance in mice;GeroScience;2024-07-09

2. Differential drug response in pulmonary arterial hypertension: The potential for precision medicine;Pulmonary Circulation;2023-10

3. Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension;Pulmonary Circulation;2022-01

4. PDE9A deficiency does not prevent chronic‐hypoxic pulmonary hypertension in mice;Physiological Reports;2021-09

5. Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction;Physiological Reports;2021-08